SCHEMBL24253937

SCHEMBL24253937

Cc1cnn(-c2cc(N3CCC4(CCCC(=O)N4c4ccc(F)c(F)c4)CC3)ncn2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.35
MEN1 O00255 1/20 0.35
CYP2C9 P11712 1/20 0.35
KMT2A Q03164 1/20 0.35
HCRTR1 O43613 3/20 0.35
HCRTR2 O43614 3/20 0.35
ALDH1A1 P00352 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SCD O00767 2/20 0.32
KCNH2 Q12809 1/20 0.32
LTC4S Q16873 1/20 0.32
DPP4 P27487 3/20 0.31
RXRA P19793 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2B Q13224 1/20 0.31
EP300 Q09472 1/20 0.30
METTL3 Q86U44 2/20 0.30
HTR1A P08908 1/20 0.30
DRD2 P14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253834 0.91 HCRTR1 (0.33) HCRTR1HCRTR2KCNH2LTC4SDPP4
SCHEMBL24253540 0.90 HCRTR1 (0.34) HCRTR1HCRTR2KCNH2LTC4SDPP4
SCHEMBL30424472 0.89 SLC34A1 (0.34) HCRTR1HCRTR2KCNH2LTC4SDPP4
SCHEMBL24253938 0.89 SLC34A1 (0.34) HCRTR1HCRTR2KCNH2LTC4SDPP4
SCHEMBL26307926 0.86 HCRTR1 (0.34) HCRTR1HCRTR2SCDKCNH2LTC4S
SCHEMBL26307925 0.86 HCRTR1 (0.33) HCRTR1HCRTR2SCDEP300
SCHEMBL24253728 0.85 JAK2 (0.33) HCRTR1HCRTR2EP300
SCHEMBL24253832 0.85 HCRTR2 (0.33) HCRTR1HCRTR2KCNH2LTC4SDPP4
SCHEMBL24253520 0.83 SCD (0.31) HCRTR1HCRTR2SCDHTR1ADRD2
SCHEMBL26307799 0.83 PARP1 (0.31) HCRTR1HCRTR2SCDHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 CYP1A2 85/4885MEN1 1544/4885CYP2C9 59/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 CYP1A2 85/4885MEN1 1544/4885CYP2C9 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.